Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus adjuvant endocrine therapy in early HR-positive, HER2-negative breast cancer
ChiCTR2400082358Phase 4Recruiting
- Sponsor
- Weihai Municipal Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalpiciclib in breast cancer (2 cohorts), sponsored by Weihai Municipal Hospital. Primary endpoint: Invasive disease-free survival. Started Mar 2024; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400082358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082358.